drug
JASCAYD
updated 3mo agoby Boehringer Ingelheim Corp
community read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying JASCAYD
- phase3A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- phase3A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- phase3A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- phase3A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
- phase3FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- phase3A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
- phase2Platform Clinical Study for Conquering Scleroderma
- phase1A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food
News(3)
- How well are AI-discovered drugs faring in the clinic?Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.biopharma_dive · 1mo ago
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 1mo ago
- Avalyn, in pursuit of better lung drugs, banks $300M in an IPOThe biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.biopharma_dive · 3mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that